Pathologic Processes × 90 days × Clear all
NCT05797246 2026-01-26

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled